BTB Pharma receives grant from Vinnova
BTB Pharma AB has been awarded a grant “Innovativa startups 2017” by Vinnova to develop a treatment for the chronic inflammatory disease, multiple sclerosis (MS).
We have previously identified components that prevented the development of MS, in an animal model. The problem was that those components were not compatible for use in humans. We have now identified new components with similar properties that can be used in humans. The goal now is to demonstrate that these new components work in the MS animal model, before taking them into the clinic.